Janja Ocvirk

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham, István Láng, Eugenio Marcuello et al. · The Lancet Oncology · 2013 · 654 citations

Medicine, Oncology, Pharmacology +10

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

Janja Ocvirk · World Journal of Gastroenterology · 2010 · 117 citations · Full text

Medicine, Oncology, Pharmacology +16

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study

Vaneja Velenik, Janja Ocvirk, Maja Marolt Mušič et al. · Radiation Oncology · 2011 · 88 citations · Full text

Medicine, Oncology, Surgery +17

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

Erik Škof, Martina Reberšek, Zvezdana Hlebanja et al. · BMC Cancer · 2009 · 70 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Management of cutaneous side‐effects of cetuximab therapy in patients with metastatic colorectal cancer

Janja Ocvirk, S Cencelj · Journal of the European Academy of Dermatology and Venereology · 2009 · 55 citations

Medicine, Dermatology, Oncology +17